Cargando…

An Updated Risk Assessment as Part of the QbD-Based Liposome Design and Development

Liposomal formulation development is a challenging process. Certain factors have a critical influence on the characteristics of the liposomes, and even the relevant properties can vary based on the predefined interests of the research. In this paper, a Quality by Design-guided and Risk Assessment (R...

Descripción completa

Detalles Bibliográficos
Autores principales: Németh, Zsófia, Pallagi, Edina, Dobó, Dorina Gabriella, Kozma, Gábor, Kónya, Zoltán, Csóka, Ildikó
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8309007/
https://www.ncbi.nlm.nih.gov/pubmed/34371762
http://dx.doi.org/10.3390/pharmaceutics13071071
_version_ 1783728419497836544
author Németh, Zsófia
Pallagi, Edina
Dobó, Dorina Gabriella
Kozma, Gábor
Kónya, Zoltán
Csóka, Ildikó
author_facet Németh, Zsófia
Pallagi, Edina
Dobó, Dorina Gabriella
Kozma, Gábor
Kónya, Zoltán
Csóka, Ildikó
author_sort Németh, Zsófia
collection PubMed
description Liposomal formulation development is a challenging process. Certain factors have a critical influence on the characteristics of the liposomes, and even the relevant properties can vary based on the predefined interests of the research. In this paper, a Quality by Design-guided and Risk Assessment (RA)-based study was performed to determine the Critical Material Attributes and the Critical Process Parameters of an “intermediate” active pharmaceutical ingredient-free liposome formulation prepared via the thin-film hydration method, collect the Critical Quality Attributes of the future carrier system and show the process of narrowing a general initial RA for a specific case. The theoretical liposome design was proved through experimental models. The investigated critical factors covered the working temperature, the ratio between the wall-forming agents (phosphatidylcholine and cholesterol), the PEGylated phospholipid content (DPPE-PEG(2000)), the type of the hydration media (saline or phosphate-buffered saline solutions) and the cryoprotectants (glucose, sorbitol or trehalose). The characterisation results (size, surface charge, thermodynamic behaviours, formed structure and bonds) of the prepared liposomes supported the outcomes of the updated RA. The findings can be used as a basis for a particular study with specified circumstances.
format Online
Article
Text
id pubmed-8309007
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-83090072021-07-25 An Updated Risk Assessment as Part of the QbD-Based Liposome Design and Development Németh, Zsófia Pallagi, Edina Dobó, Dorina Gabriella Kozma, Gábor Kónya, Zoltán Csóka, Ildikó Pharmaceutics Article Liposomal formulation development is a challenging process. Certain factors have a critical influence on the characteristics of the liposomes, and even the relevant properties can vary based on the predefined interests of the research. In this paper, a Quality by Design-guided and Risk Assessment (RA)-based study was performed to determine the Critical Material Attributes and the Critical Process Parameters of an “intermediate” active pharmaceutical ingredient-free liposome formulation prepared via the thin-film hydration method, collect the Critical Quality Attributes of the future carrier system and show the process of narrowing a general initial RA for a specific case. The theoretical liposome design was proved through experimental models. The investigated critical factors covered the working temperature, the ratio between the wall-forming agents (phosphatidylcholine and cholesterol), the PEGylated phospholipid content (DPPE-PEG(2000)), the type of the hydration media (saline or phosphate-buffered saline solutions) and the cryoprotectants (glucose, sorbitol or trehalose). The characterisation results (size, surface charge, thermodynamic behaviours, formed structure and bonds) of the prepared liposomes supported the outcomes of the updated RA. The findings can be used as a basis for a particular study with specified circumstances. MDPI 2021-07-13 /pmc/articles/PMC8309007/ /pubmed/34371762 http://dx.doi.org/10.3390/pharmaceutics13071071 Text en © 2021 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Németh, Zsófia
Pallagi, Edina
Dobó, Dorina Gabriella
Kozma, Gábor
Kónya, Zoltán
Csóka, Ildikó
An Updated Risk Assessment as Part of the QbD-Based Liposome Design and Development
title An Updated Risk Assessment as Part of the QbD-Based Liposome Design and Development
title_full An Updated Risk Assessment as Part of the QbD-Based Liposome Design and Development
title_fullStr An Updated Risk Assessment as Part of the QbD-Based Liposome Design and Development
title_full_unstemmed An Updated Risk Assessment as Part of the QbD-Based Liposome Design and Development
title_short An Updated Risk Assessment as Part of the QbD-Based Liposome Design and Development
title_sort updated risk assessment as part of the qbd-based liposome design and development
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8309007/
https://www.ncbi.nlm.nih.gov/pubmed/34371762
http://dx.doi.org/10.3390/pharmaceutics13071071
work_keys_str_mv AT nemethzsofia anupdatedriskassessmentaspartoftheqbdbasedliposomedesignanddevelopment
AT pallagiedina anupdatedriskassessmentaspartoftheqbdbasedliposomedesignanddevelopment
AT dobodorinagabriella anupdatedriskassessmentaspartoftheqbdbasedliposomedesignanddevelopment
AT kozmagabor anupdatedriskassessmentaspartoftheqbdbasedliposomedesignanddevelopment
AT konyazoltan anupdatedriskassessmentaspartoftheqbdbasedliposomedesignanddevelopment
AT csokaildiko anupdatedriskassessmentaspartoftheqbdbasedliposomedesignanddevelopment
AT nemethzsofia updatedriskassessmentaspartoftheqbdbasedliposomedesignanddevelopment
AT pallagiedina updatedriskassessmentaspartoftheqbdbasedliposomedesignanddevelopment
AT dobodorinagabriella updatedriskassessmentaspartoftheqbdbasedliposomedesignanddevelopment
AT kozmagabor updatedriskassessmentaspartoftheqbdbasedliposomedesignanddevelopment
AT konyazoltan updatedriskassessmentaspartoftheqbdbasedliposomedesignanddevelopment
AT csokaildiko updatedriskassessmentaspartoftheqbdbasedliposomedesignanddevelopment